Major indices were in the green earlier on Wednesday as traders digested more bank earnings and another key inflation report.

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Amgen, with a price target of $300.00. The company’s shares closed last Friday at $295.27. Schott covers the ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

JPMorgan initiated coverage of Circle stock with an underweight rating and $80 price target, citing competition and regulation as key risks to growth.

Apple’s stock took a minor confidence hit today, as JPMorgan lowered its price target, though the firm kept its overall rating intact.

Regeneron holds an average rating of “Moderate Buy,” with 20 analysts still recommending it as a solid pick and three even going all-in with “strong buy” ratings. With the average price target now at ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Regeneron Pharmaceuticals faced a round of target cuts from major financial institutions, with JPMorgan Chase & Co. leading the charge by lowering its price objective from $950 to $800. Despite the ...